Module 1: Juvenile Toxicology

Recorded On: 09/29/2022

image
image


This eLearning module will focus on the principles of juvenile toxicology. The lecture will be offered with two main themes: the first will address whether a juvenile animal study should be conducted, followed by a focus on how it could be conducted. The first section will provide an overview of juvenile toxicology from a regulatory perspective. This will include the ICH S11 guidance for nonclinical juvenile animal testing to support pediatric medicine development (released in 2020), which proposes a weight-of-evidence approach to decide whether a juvenile animal study is warranted. If a study is warranted, this exercise informs the main objectives of the juvenile animal study, including any customized additional endpoints to the ‘core’ endpoints provided in ICH S11. The second part of the session will focus on study design and delivery approaches to juvenile animal testing for pharmaceutical and nonpharmaceutical industries. Topics addressed will include selection of juvenile toxicology species, age of the animals during treatment, both with strong consideration of comparative organ development. As ADME systems are often immature in juvenile animals, dose range-finding approaches will be discussed in detail.  Since rodent juvenile animal studies are the most common, study design considerations for treatment of preweaning animals within a litter will be reviewed. Lastly, interpretation considerations unique to juvenile animal studies and application of results to human risk assessment will be discussed with a focus on pharmaceuticals. 

Susan Laffan, PhD

Susan Laffan, PhD

Head of the Nonclinical Global Investigative Safety

GlaxoSmithKline

Susan Laffan is currently a Head of the Nonclinical Global Investigative Safety group at GlaxoSmithKline, she is a toxicologist with over 18 years of pharmaceutical industry experience. Susan is the nonclinical chair of the GSK’s pediatric advisory network providing advice to drug development teams on their pediatric development plans. Dr. Laffan represented PhRMA on the ICH S11 Working Group. She is an expert in reproductive and developmental toxicology and has been directly involved in the drug development teams supporting the safety assessment of compounds from discovery through post-marketing. Susan earned a PhD in toxicology from the University of North Carolina at Chapel Hill, conducting her dissertation at the USEPA, Research Triangle Park, NC. In addition, she is on the ILSI/HESI DART Technical Committee.

Key:

Complete
Failed
Available
Locked
Module 1: Juvenile Toxicology
Module 1: Juvenile Toxicology, Susan Laffan, PhD
Recorded 09/29/2022  |  90 minutes
Recorded 09/29/2022  |  90 minutes As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Survey
13 Questions
13 Questions ACT values your feedback. Please help us continue to provide high-quality educational offerings by completing this short survey. The survey will become available after you have met the minimum viewing requirement for the recording. Once you complete the survey, your certificate of completion will become available on your dashboard or for download.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Your certificate of completion will become available after you have met the minimum viewing requirement and completed the module survey.